Computer-aided design of antimicrobial peptides

Current Pharmaceutical Analysis

Volumn 6, Issue 2, 2010, Pages 66-75

  Fjell, Christopher D ^a   Hancock, Robert E W ^a   Jenssen, Håvard ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ROSKILDE UNIVERSITY   (Denmark)

Author keywords

Antimicrobial peptides; Artificial neural network; P. aeruginosa; Partial least square projections to latent structures; Prediction of activity; Quantitative structure activity relationships

Indexed keywords

LACTOFERRICIN; POLYPEPTIDE ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; ARTIFICIAL NEURAL NETWORK; CHEMICAL PARAMETERS; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 77952917455     PISSN: 15734129     EISSN: None     Source Type: Journal    
DOI: 10.2174/157341210791202645     Document Type: Article

References (75)

1. Moran, G.J.; Mount, J., Update on emerging infections: news from the Centers for Disease Control and Prevention. Ann. Emerg. Med., 2003, 41(1), 148-151.
2. Wenzel, R.P. The antibiotic pipeline-challenges, costs, and values. N. Engl. J. Med., 2004, 351(6), 523-526.
3. Norrby, S.R. Alert to a European epidemic. Nature, 2004, 431(7008), 507-508.
4. Projan, S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol., 2003, 6(5), 427-430.
5. Chan, P.F.; Holmes, D.J.; Payne, D.J. Finding the gems using genomic discovery: antibacterial drug discovery strategies - the successes and the challenges. DDT: Ther. Strategies., 2004, 1, 519-527.
6. Hancock, R.E.W.; Sahl, H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol., 2006, 24(12), 1551-1557.
7. Jenssen, H.; Hamill, P.; Hancock, R.E.W. Peptide antimicrobial agents. Clin. Microbiol. Rev., 2006, 19(3), 491-511.
8. Finlay, B.B.; Hancock, R.E.W. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol., 2004, 2(6), 497-504.
9. Hancock, R.E.W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis., 2001, 1(3), 156-164.
10. Fjell, C.D.; Hancock, R.E.W.; Cherkasov, A. AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics, 2007, 23(9), 1148-1155.
11. Fjell, C.D.; Jenssen, H.; Fries, P.; Aich, P.; Griebel, P.; Hilpert, K.; Hancock, R.E.W.; Cherkasov, A. Identification of novel host defense peptides and the absence of alpha-defensins in the bovine genome. Proteins, 2008, 73, 420-430.
12. Bowdish, D.M.; Davidson, D.J.; Hancock, R.E.W. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci., 2005, 6(1), 35-51.
13. Boman, H.G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol., 1995, 13, 61-92.
14. Hilpert, K.; Elliott, M.R.; Volkmer-Engert, R.; Henklein, P.; Donini, O.; Zhou, Q.; Winkler, D.F.; Hancock, R.E.W. Sequence requirements and an optimization strategy for short antimicrobial peptides. Chem. Biol., 2006, 13(10), 1101-1107.
15. Hilpert, K.; Volkmer-Engert, R.; Walter, T.; Hancock, R.E.W. High-throughput generation of small antibacterial peptides with improved activity. Nat. Biotechnol., 2005, 23(8), 1008-1012.
16. Perkins, R.; Fang, H.; Tong, W.; Welsh, W.J. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ. Toxicol. Chem., 2003, 22(8), 1666-1679.
17. Hancsh, C.; Maloney, P.P.; Fujita, T.; Muri, R.M. Correlation of biological activity of phenozyacetic acid with hammett substituent constants and partition coefficients. Nature, 1962, 194, 178-180.
18. Strom, M.B.; Rekdal, O.; Stensen, W.; Svendsen, J.S. Increased antibacterial activity of 15-residue murine lactoferricin derivatives. J. Pept. Res., 2001, 57(2), 127-139.
19. Cruciani, G.; Pastor, M.; Guba, W. VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci., 2000, 11(Suppl 2), S29-39.
20. Zamora, I.; Oprea, T.; Cruciani, G.; Pastor, M.; Ungell, A.L. Surface descriptors for protein-ligand affinity prediction. J. Med. Chem., 2003, 46(1), 25-33.
21. Cherkasov, A. Inductive QSAR descriptors, distinguishing compounds with antibacterial activity by artificial neural network. Int. J. Mol. Sci., 2005, 6, 63-86.
22. Sneath, P.H. Relations between chemical structure and biological activity in peptides. J. Theor. Biol., 1966, 12(2), 157-195.
23. Hellberg, S.; Sjostrom, M.; Wold, S. The prediction of bradykinin potentiating potency of pentapeptides. An example of a peptide quantitative structure-activity relationship. Acta. Chem. Scand. B, 1986, 40(2), 135-140.
24. Hellberg, S.; Sjostrom, M.; Skagerberg, B.; Wold, S., Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem., 1987, 30(7), 1126-35.
25. Sandberg, M.; Eriksson, L.; Jonsson, J.; Sjostrom, M.; Wold, S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J. Med. Chem., 1998, 41(14), 2481-2491.
26. Jenssen, H.; Lejon, T.; Hilpert, K.; Fjell, C.D.; Cherkasov, A.; Hancock, R.E.W. Evaluating different descriptors for model design of antimicrobial peptides with enhanced activity toward P. aeruginosa. Chem. Biol. Drug. Des., 2007, 70(2), 134-142.
27. Yang, N.; Lejon, T.; Rekdal, O. Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J. Pept. Sci., 2003, 9(5), 300-311.
28. Lejon, T.; Strom, M.B.; Svendsen, J.S. Antibiotic activity of pentadecapeptides modelled from amino acid descriptors. J. Pept. Sci., 2001, 7(2), 74-81.
29. Jenssen, H.; Gutteberg, T.J.; Lejon, T. Modelling of anti-HSV activity of lactoferricin analogues using amino acid descriptors. J. Pept. Sci., 2005, 11(2), 97-103.
30. Eriksson, L.; Johansson, E.; Kettaneh-Wold, N.; Trygg, J.; Wikström, C.; Wold, S. Multi- and Megavariate Data Analysis - Basic Principles and Applications. Umetrics: Umeå 2006, Vol. 1, pp. 1-425.
31. Hastie, T.; Tibshirani, R.; Friedman, J. The elements of statistical learning data mining, inference, and prediction. Springer: New York 2001, pp. 66-67.
32. Eriksson, L.; Jonsson, J.; Hellberg, S.; Lindgren, F.; Skagerberg, B.; Sjostrom, M.; Wold, S. Peptide QSAR on substance P analogues, enkephalins and bradykinins containing L- and D-amino acids. Acta. Chem. Scand., 1990, 44(1), 50-55.
33. Wold, S.; Albano, C.; Dunn, III. W.J.; Edlund, U.; Esbensen, K.; Geladi, P.; Hellberg, S.; Johansson, E.; Lindberg, W.; Sjöström, M. In: Chemometrics - mathematics and statistics in chemistry; Kowalski, B.R., Ed.; D. Reidel Publishing Company: Dordrecht 1984, Vol. 138, pp. 17-95.
34. Wold, S.; Sjöström, M., In: Chemometrics: theory and application, Kowalski, B. R., Ed.; American Chemical Society: washington, 1977; Vol. 52, pp. 243-282.
35. Hancock, R.E.W.; Rozek, A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS. Microbiol. Lett., 2002, 206(2), 143-149.
36. Dathe, M.; Wieprecht, T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim. Biophys. Acta., 1999, 1462(1-2), 71-87.
37. Hancock, R.E.W.; Patrzykat, A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr. Drug Targets Infect. Disord., 2002, 2(1), 79-83.
38. Andreu, D.; Rivas, L. Animal antimicrobial peptides: an overview. Biopolymers, 1998, 47(6), 415-433.
39. Epand, R.M.; Vogel, H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta., 1999, 1462(1-2), 11-28.
40. Matsuzaki, K.; Sugishita, K.; Ishibe, N.; Ueha, M.; Nakata, S.; Miyajima, K.; Epand, R.M. Relationship of membrane curvature to the formation of pores by magainin 2. Biochemistry, 1998, 37(34), 11856-11863.
41. Sitaram, N.; Nagaraj, R. Interaction of antimicrobial peptides with biological and model membranes: structural and charge requirements for activity. Biochim. Biophys. Acta., 1999, 1462(1-2), 29-54.
42. Chapple, D.S.; Mason, D.J.; Joannou, C.L.; Odell, E.W.; Gant, V.; Evans, R.W. Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect. Immun. 1998, 66(6), 2434-2440.
43. Vorland, L.H.; Ulvatne, H.; Rekdal, O.; Svendsen, J.S. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand. J. Infect. Dis., 1999, 31(5), 467-473.
44. Faber, C.; Stallmann, H.P.; Lyaruu, D.M.; Joosten, U.; von Eiff, C.; van Nieuw Amerongen, A.; Wuisman, P.I. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob. Agents Chemother., 2005, 49(6), 2438-2444.
45. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin.Biochim. Biophys. Acta., 1992, 1121(1-2), 130-136.
46. Strom, M.B.; Haug, B.E.; Rekdal, O.; Skar, M.L.; Stensen, W.; Svendsen, J.S. Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem. Cell Biol., 2002, 80(1), 65-74.
47. Vorland, L.H.; Ulvatne, H.; Andersen, J.; Haukland, H.; Rekdal, O.; Svendsen, J. S.; Gutteberg, T.J., Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand. J. Infect. Dis., 1998, 30(5), 513-517.
48. Ulvatne, H.; Samuelsen, O.; Haukland, H.H.; Kramer, M.; Vorland, L.H. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS. Microbiol. Lett., 2004, 237(2), 377-384.
49. Friedrich, C.L.; Moyles, D.; Beveridge, T.J.; Hancock, R.E.W., Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother., 2000, 44(8), 2086-2092.
50. Powers, J.P.; Rozek, A.; Hancock, R.E.W. Structure-activity relationships for the beta-hairpin cationic antimicrobial peptide polyphemusin I. Biochim. Biophys. Acta., 2004, 1698(2), 239-250.
51. Kustanovich, I.; Shalev, D.E.; Mikhlin, M.; Gaidukov, L.; Mor, A. Structural requirements for potent versus selective cytotoxicity for antimicrobial dermaseptin S4 derivatives. J. Biol. Chem., 2002, 277(19), 16941-16951.
52. Zelezetsky, I.; Pag, U.; Sahl, H.G.; Tossi, A. Tuning the biological properties of amphipathic alpha-helical antimicrobial peptides: rational use of minimal amino acid substitutions. Peptides, 2005, 26(12), 2368-2376.
53. Lejon, T.; Stiberg, T.; Strom, M.B.; Svendsen, J.S. Prediction of antibiotic activity and synthesis of new pentadecapeptides based on lactoferricins. J. Pept. Sci., 2004, 10(6), 329-335.
54. Jenssen, H.; Gutteberg, T.J.; Lejon, T. Modelling the anti-herpes simplex virus activity of small cationic peptides using amino acid descriptors. J. Pept. Res., 2005, 66 (Suppl 1), 48-56.
55. Jenssen, H.; Gutteberg, T.J.; Rekdal, O.; Lejon, T. Prediction of activity, synthesis and biological testing of anti-HSV active peptides. Chem. Biol. Drug Des., 2006, 68(1), 58-66.
56. Sjöström, M.; Eriksson, L. In Chemometircs methods in molecular design, Waterbeemd, H.V.D., Ed.; VCH Verlagsgesellshaft mbH: Weinheim 1995, pp. 63-90.
57. Miyazawa, S.; Jernigan, R.L. Residue-residue potentials with a favorable contact pair term and an unfavorable high packing density term, for simulation and threading. J. Mol. Biol., 1996, 256(3), 623-644.
58. Jenssen, H.; Fjell, C.D.; Cherkasov, A.; Hancock, R.E.W. QSAR modeling and computer-aided design of antimicrobial peptides. J. Pept. Sci., 2008, 14(1), 110-114.
59. Jenssen, H. Anti herpes simplex virus activity of lactoferrin/lactoferricin - an example of antiviral activity of antimicrobial protein/peptide. Cell Mol. Life Sci., 2005, 62(24), 3002-3013.
60. Cherkasov, A. Can 'Bacterial-Metabolite-Likeness' model improve odds of 'in silico' antibiotic discovery? J. Chem. Inf. Model, 2006, 46(3), 1214-1222.
61. Karakoc, E.; Sahinalp, S.C.; Cherkasov, A. Comparative QSAR-and fragments distribution analysis of drugs, druglikes, metabolic substances, and antimicrobial compounds. J. Chem. Inf. Model, 2006, 46(5), 2167-2182.
62. Skerlavaj, B.; Benincasa, M.; Risso, A.; Zanetti, M.; Gennaro, R. SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS. Lett., 1999, 463(1-2), 58-62.
63. Sawai, M.V.; Waring, A.J.; Kearney, W.R.; McCray, P.B., Jr.; Forsyth, W.R.; Lehrer, R.I.; Tack, B.F. Impact of single-residue mutations on the structure and function of ovispirin/novispirin antimicrobial peptides. Protein Eng., 2002, 15(3), 225-232.
64. Taboureau, O.; Olsen, O.H.; Nielsen, J.D.; Raventos, D.; Mygind, P.H.; Kristensen, H.H. Design of novispirin antimicrobial peptides by quantitative structure-activity relationship. Chem. Biol. Drug Des., 2006, 68(1), 48-57.
65. Patel, S.; Stott, I.P.; Bhakoo, M.; Elliott, P. Patenting computer designed peptides. J. Comput. Aided. Mol. Des., 1998, 12(6), 543-56.
66. Cherkasov, A.; Hilpert, K.; Jenssen, H.; Fjell, C.D.; Waldbrook, M.; Mullaly, S.C.; Volkmer, R.; Hancock, R.E.W. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem. Biol., 2009, 4(1), 65-74.
67. Fjell, C.D.; Jenssen, H.; Hilpert, K.; Cheung, W.A.; Panté, N.; Hancock, R.E.W.; Cherkasov, A. Identification of novel antibacterial peptides by chemoinformatics and machine learning. J. Med. Chem., 2009, 52(2), 2006-2015.
68. Weaver, D.C. Applying data mining techniques to library design, lead generation and lead optimization. Curr. Opin. Chem. Biol., 2004, 8(3), 264-270.
69. Sawai, M.V.; Jia, H.P.; Liu, L.; Aseyev, V.; Wiencek, J.M.; McCray, P.B., Jr.; Ganz, T.; Kearney, W.R.; Tack, B.F. The NMR structure of human beta-defensin-2 reveals a novel alpha-helical segment. Biochemistry, 2001, 40(13), 3810-3816.
70. Powers, J.P.; Tan, A.; Ramamoorthy, A.; Hancock, R.E.W. Solution structure and interaction of the antimicrobial polyphemusins with lipid membranes. Biochemistry, 2005, 44(47), 15504-15513.
71. Gudmundsson, G.H.; Agerberth, B.; Odeberg, J.; Bergman, T.; Olsson, B.; Salcedo, R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem., 1996, 238(2), 325-332.
72. Wang, G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem., 2008, 283(47), 32637-32643.
73. Rozek, A.; Friedrich, C.L.; Hancock, R.E.W., Structure of the bovine antimicrobial peptide indolicidin bound to dodecylphosphocholine and sodium dodecyl sulfate micelles. Biochemistry, 2000, 39(51), 15765-15774.
74. Koradi, R.; Billeter, M.; Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graph., 1996, 14(1), 29-32.
75. Hwang, P.M.; Zhou, N.; Shan, X.; Arrowsmith, C.H.; Vogel, H.J., Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry, 1998, 37(12), 4288-4298.